Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 18];9(6):s646. Available from: https://skin.dermsquared.com/skin/article/view/3869